Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puma Biotechnology (NQ: PBYI )

2.880 +0.050 (+1.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 144,700
Open 2.810
Bid (Size) 2.530 (10)
Ask (Size) 2.990 (100)
Prev. Close 2.830
Today's Range 2.770 - 2.906
52wk Range 2.130 - 7.730
Shares Outstanding 47,509,765
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire

Performance

YTD
-36.35%
-36.35%
1 Month
+15.20%
+15.20%
3 Month
-21.31%
-21.31%
6 Month
-42.51%
-42.51%
1 Year
+22.03%
+22.03%

More News

Read More
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Where Puma Biotechnology Stands With Analysts
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Join Russell 3000 Index
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Puma Biotechnology Reports First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Via InvestorPlace
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.